Page results
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
The palliative care team at UCLH provides specialist palliative and end-of-life care to any patient who has a life-limiting illness, and offers support to families and carers.
-
At University College London Hospitals NHS Foundation Trust (UCLH) we value our reputation for top quality care and financial probity and conduct our business in an ethical manner.
-
Today, 11 February, marks the tenth anniversary of the International Day of Women and Girls in Science, which seeks to bring gender equality in science and promote role models to inspire girls and women into scientific professions.
-
Art and creativity can be a real tonic for health, says UCLH arts curator Guy Noble.
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
-
Lizzi Jordan, who received life-saving treatment at UCLH before going on to win a gold medal for cycling in the 2024 Paralympic Games, paid tribute to UCLH staff as she was made a Member of the British Empire (MBE).
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
-
SUMMIT Study results on the benefits of large-scale screening for lung cancer are published in The Lancet Oncology today (26 March), ahead of the formal addition of lung cancer screening to the UK national screening programme from 1 April.
File results
-
FOI/2023/0237 - Software solution to manage patient e-consent for school vaccinations/ immunisations and waitlist validation
-
FOI/2023/0244 - IT systems for digital dictation, speech recognition, outsourced transcription, video consultation and health information systems
-
FOI/2023/0247 - Treatment guidelines for Idiopathic Pulmonary Fibrosis
-
FOI/2023/0242 - Treatment of Haemophilia A
-
FOI/2023/0249 - Treatments for clotting disorders - Haemophilia B, Von Willebrand Disease
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0262 - Clinical trial participation
-
FOI/2023/0275 - Trust statistics on spiking
-
FOI/2023/0360 - Minutes of Board of Director meetings and Declarations of Interests (DoI) statements 2008-2023